Abstracts Archive - Page 2015 of 2425 - ACR Meeting Abstracts

Abstract Number: 543 • 2014 ACR/ARHP Annual Meeting
Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée M. van der Heijde¹, Atul A. Deodhar², Owen Davies³, Tommi Nurminen⁴ and Martin Rudwaleit⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Arthritis and Rheumatic diseases, Oregon Health and Science University, Portland, OR, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Endokrinologikum, Berlin, Germany
Background/Purpose: Early response to anti-TNF therapy has been shown to be a strong predictor of good long-term outcomes in ankylosing spondylitis (AS).1 However, early identification…
Abstract Number: 542 • 2014 ACR/ARHP Annual Meeting
Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis – a Cohort Study
Lihi Eder¹, Arane Thavaneswaran¹, Vinod Chandran¹, Hua Shen², Richard J. Cook² and Dafna D. Gladman¹, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose The prevalence of cardiovascular (CV) morbidity is increased in patients with psoriatic arthritis (PsA). CV risk is only partially explained by traditional CV risk…
Abstract Number: 541 • 2014 ACR/ARHP Annual Meeting
Collagen II Neo-Epitopes in Spondyloarthritis.
Heidi Lausten Munk¹, Natasja Staehr Gudmann², Anne Friesgaard Christensen³, Leif Ejstrup⁴, Grith Lykke Sørensen⁵, Anne Gitte Loft³, Anne C. Bay-Jensen², Anne Sofie Siebuhr² and Peter Junker¹, ¹Department of Rheumatology, Odense University Hospital, Odense, Denmark, ²Cartilage Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Department of Rheumatology, Vejle Hospital, Vejle, Denmark, ⁴Department of Rheumatology, Esbjerg Hospital, Esbjerg, Denmark, ⁵Cardiovascular and Renal Research, Institute of Molecular Medicin, University of Southern Denmark, Odense, Denmark
Background/Purpose Spondyloarthritis (SpA) is characterized by aseptic inflammation of the axial skeleton which may ultimately lead to irreversible deformities due to bony ankylosis. Occasionally, peripheral…
Abstract Number: 540 • 2014 ACR/ARHP Annual Meeting
Two Years Sacroiliac Radiographic Progression Rate and Influence of Baseline Markers of Inflammation in Recent Onset Spondyloarthritis
Maxime Dougados¹, Christophe Demattei², Rosaline van den Berg³, Viet Vo Hoang⁴, Fabrice Thévenin⁵, Monique Reijnierse⁶, Damien Loeuille⁷, Antoine Feydy⁸, Pascal Claudepierre⁹ and Désirée van der Heijde¹⁰, ¹INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ²Service BESPIM, CHU, Nimes, France, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of radiology, Lyon, France, ⁵Radiology B, Paris Descartes University, Côchin Hospital, APHP, Paris, France, ⁶Radiology, Leiden University Medical Center, Leiden, Netherlands, ⁷Rhumatology, CHU Nancy, Vandoeuvre Les Nancy, France, ⁸Paris Descartes University, Radiology B department, Cochin Hospital, paris, France, ⁹Rheumatology, Paris-Est University; LIC EA4393; APHP, Henri Mondor Hospital, Creteil, France, ¹⁰LUMC, Leiden, Netherlands
Background/Purpose: According to the ASAS axial spondyloarthritis (SpA) criteria, patients suffering from inflammatory back pain (IBP) can be recognized as suffering from axial SpA even…
Abstract Number: 559 • 2014 ACR/ARHP Annual Meeting
Ultra Sonographic Evaluation of the Anterior Chest Wall in Spondyloarthritis. a Prospective Study
Frank Verhoeven¹, Xavier Guillot², Marie Godfrin-Valnet³, Clément Prati⁴ and Daniel Wendling⁴, ¹Rheumatology, CHU jean Minjoz, Besançon, France, ²rheumatology, Besançon, France, ³Rheumatology, CHRU, Besançon, France, ⁴Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: Anterior chest wall (ACW) involvement is a characteristic feature of spondyloarthritis (SpA), even in early stages, but its paraclinic exploration is not standardized.The aim…
Abstract Number: 558 • 2014 ACR/ARHP Annual Meeting
Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index
Philip J. Mease¹, Denis Poddubnyy², Su Chen³ and Jaclyn K. Anderson³, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL
Background/Purpose: C-reactive protein (CRP), an objective measure of active inflammation, has been associated with obesity, with both overweight and obese individuals more likely to have…
Abstract Number: 557 • 2014 ACR/ARHP Annual Meeting
Translation and Cross-Cultural Adaptation of the ASAS Health Index and the environmental Item Set into 15 Languages
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen³, Wilson Bautista - Molano⁴, Ruben Burgos-Vargas⁵, Praveena Chiowchanwisawakit⁶, M Tuncay Duruoz⁷, Bassel El-Zorkany⁸, Inna Gaydukova⁹, Ivette Essers¹⁰, Pál Géher¹¹, Laure Gossec¹², Simeon Grazio¹³, Jieruo Gu¹⁴, Muhammad Asim Khan¹⁵, Tae.Jong Kim¹⁶, Walter P. Maksymowych¹⁷, Helena Marzo-Ortega¹⁸, Victoria Navarro-Compan¹⁹, Ignazio Olivieri²⁰, Dimos Patrikos²¹, Fernando Pimentel-Santos²², Filip van Den Bosch²³, Jane Zochling²⁴ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Dept of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Spondyloarthritis Group. Rheumatology Division. Hospital Militar Central/Universidad de La Sabana. Bogotá. Colombia, Bogotá, Colombia, ⁵Rheumatology, Universidad Nacional Autónoma de México, Mexico, Mexico, ⁶The Offices at Central World,, Siriraj Hospital, Bangkok, Thailand, ⁷Dept of PM&R, Rheumatology Clinic, Marmara Univ Med Schl, Istanbul, Turkey, ⁸Cairo University, Cairo, Egypt, ⁹Hospital Therapy, Saratov State Medical University, Saratov, Russia, ¹⁰School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ¹¹Budai Irgalmasrendi Korhaz, Budapest, Hungary, ¹²Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ¹³Clinical Hospital Center Sestre Milosrdnice, Zagreb, Croatia, ¹⁴Rheumatology, The Affiliated Third Hospital of Sun Yat-san University, Rheumatology, Guangzhou, China, ¹⁵Medicine/ Rheumatology, CASE at MetroHealth Med Center, Cleveland, OH, ¹⁶Chonnam Nat`l University Medical School&Hospital, Chonnam, South Korea, ¹⁷Medicine, University of Alberta, Edmonton, AB, Canada, ¹⁸University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ¹⁹University Hospital La Paz, Madrid, Spain, ²⁰Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna delle Grazie Hospital of Matera, Potenza, Italy, ²¹138 MESOGEION AVE & KATECHAKI, 401 Military Hospital Of Athens, Athens, Greece, ²²Rheumatology, Centro Hospitalar de Lisboa Ocidental, Hospital Egas Moniz, Lisboa, Portugal, ²³Rheumatology, Department of Rheumatology Ghent University Hospital, Ghent, Belgium, ²⁴Menzies Research Institute Tasmania, Hobart, Australia
Background/Purpose: The ASAS Health Index (ASAS HI) is a unidimensional questionnaire measuring health and impairment in functioning in patients with spondyloarthritis (SpA). The ASAS HI…
Abstract Number: 556 • 2014 ACR/ARHP Annual Meeting
Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling³, ¹Rheumatology, CHRU, Besançon, France, ²Investigation Center, CHRU, Besançon, France, ³Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: Spondyloarthritis (SpA) activity varies with time and treatment, but to date no clear definition of a flare of the disease is available. The aim…
Abstract Number: 555 • 2014 ACR/ARHP Annual Meeting
Urinary Excretion of Type II Collagen C-Telopeptide and Glucosyl-Galactosyl-Pyridinoline As Prognostic Biomarkers in Early Spondyloarthritis
Elisa Trujillo¹ and Maria del Mar Trujillo², ¹Servicio de Reumatologia, Hospital Universitario de Canarias, La Laguna, Tenerife, Spain, ²Servicio de evaluacion y planificacion, Servicio Canario de la Salud, Tenerife, Spain
Background/Purpose: The search for biomarkers in spondyloarthritis (SpA) is of great interest because of their diagnostic and prognostic role in the treatment of these diseases.…
Abstract Number: 554 • 2014 ACR/ARHP Annual Meeting
Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain
Maureen Dubreuil, Rheumatology, Boston VA HealthCare System, Boston, MA; Rheumatology, Boston University Medical Center, Boston, MA
Background/Purpose: Spondyloarthropathies (SpA) have been associated with increased risk of myocardial infarction (MI), however it remains unclear if the risk is related solely to…
Abstract Number: 553 • 2014 ACR/ARHP Annual Meeting
Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Joachim Sieper¹, Désirée van der Heijde², Nupun A. Varothai³ and Jaclyn K. Anderson³, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³AbbVie Inc., North Chicago, IL
Background/Purpose: To compare 1) extra-articular manifestations, 2) baseline comorbidities, and 3) adverse event (AE) rates with long-term adalimumab (ADA) therapy in patients (pts) treated in…
Abstract Number: 552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvement in Physical Function, Health-Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis
Désirée van der Heijde¹, Manish Mittal², Naijun Chen², Aileen L. Pangan² and Avani D. Joshi², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²AbbVie Inc., North Chicago, IL
Background/Purpose: In the ABILITY-1 trial, adalimumab (ADA) treatment for 12 weeks was associated with improved clinical and health-related quality of life (HRQOL) outcomes among patients…
Abstract Number: 551 • 2014 ACR/ARHP Annual Meeting
Predictors Associated with Rheumatologist Referral Time in Patients with Ankylosing Spondylitis
Atul A. Deodhar¹, Manish Mittal², Patrick Reilly², Yanjun Bao², Shivaji Manthena², Jaclyn K. Anderson² and Avani D. Joshi², ¹Oregon Health and Sciences University, Portland, OR, ²AbbVie Inc., North Chicago, IL
Background/Purpose: Average delay between symptom onset and diagnosis of ankylosing spondylitis (AS) has been reported as 8–12.8 years1,2. This study assessed delay in AS diagnosis…
Abstract Number: 534 • 2014 ACR/ARHP Annual Meeting
Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block
Amit Saxena¹, Peter M. Izmirly², Sung Won Han³, Andrew Markham⁴, Robert M. Clancy⁵ and Jill P. Buyon⁵, ¹Rheumatology, New York University School of Medicine, New York, NY, ²Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Population Health, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY, ⁵Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose Women with Sjogren’s Syndrome (SS) and anti-Ro antibodies face the risk of a pregnancy complicated by fetal congenital heart block (CHB). Identification of maternal…
Abstract Number: 533 • 2014 ACR/ARHP Annual Meeting
Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren’s Syndrome
Kyung-Eun Lee¹, Dong-Jin Park¹ and Shin-Seok Lee², ¹Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ²Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea
Background/Purpose Chemokines, which control inflammatory cell migration, have been shown to play important roles in the inflammatory processes associated with Sjögren’s Syndrome (SS). CCL21 and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].